Similar articles

• Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.

  Wels W, Groner B, Hynes NE. Wels W, et al. Curr Top Microbiol Immunol. 1996;213 ( Pt 3):113-28. doi: 10.1007/978-3-642-80071-9_8. Curr Top Microbiol Immunol. 1996. PMID: 8815001 Review. No abstract available.
• A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.

  Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K, Imai K, Matsuno S, Kumagai I, Kudo T. Hayashi H, et al. Cancer Immunol Immunother. 2004 Jun;53(6):497-509. doi: 10.1007/s00262-003-0465-9. Epub 2003 Nov 25. Cancer Immunol Immunother. 2004. PMID: 14648071 Free PMC article.
• Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.

  Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C. Shalaby MR, et al. Clin Immunol Immunopathol. 1995 Feb;74(2):185-92. doi: 10.1006/clin.1995.1027. Clin Immunol Immunopathol. 1995. PMID: 7828373
• Improving the efficacy of antibody-based cancer therapies.

  Carter P. Carter P. Nat Rev Cancer. 2001 Nov;1(2):118-29. doi: 10.1038/35101072. Nat Rev Cancer. 2001. PMID: 11905803 Review.
• Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.

  Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M. Renner C, et al. Science. 1994 May 6;264(5160):833-5. doi: 10.1126/science.8171337. Science. 1994. PMID: 8171337